Table 4:

Recent Trials Addressing Sarcomatoid Features in Advanced RCC

			Histology
Study	Treatment Agent	N	Clear Cell	Papillary	Chromophobe	Other	Sarcomatoid*	ORR**
KEYNOTE 427	Pembrolizumab	165	0%	72%	13%	16%	23%	42%
KEYNOTE 426	Pembrolizumab + Axitinib	861	100%	0%	0%	0%	12%	Pembrolizumab + Axitinib 59%, Sunitinib 32%
CheckMate 9ER	Nivolumab + Cabozantinib vs. Sunitinib	651	100%	0%	0%	0%	12%	Nivolumab + Cabozantinib 56%, Sunitinib 22%
Immotion 151	Atezolizumab + Bevacizumab vs. Sunitinib	915	92%	0%	0%	0%	16%	Atezolizumab + Bevacizumab 49%, Sunitinib 14%
CheckMate 214	Nivolumab + Ipilimumab	1096	100%	0%	0%	0%	13%	Nivolumab + Ipilimumab 57%, Sunitinib 19%
Javelin 101	Avelumab + Axitinib vs. Sunitinib	886	100%	0	0	0	12%	Avelumab + Axitinib 47%, Sunitinib 21%
NCT02724878	Atezolizumab + Bevacizumab	60	30%	20%	17%	33%	42%	46%

ORR = objective response rate;

^*Sarcomatoid features can be found in any histologic subtype and are described distinctly from other histologic subtypes;

^**Reported response rates specific to sarcomatoid histology